Dr. Matthew Cherry, D.O

NPI: 1457376865
Total Payments
$135,775
2024 Payments
$27,360
Companies
5
Transactions
82
Medicare Patients
23
Medicare Billing
$171.91

Payment Breakdown by Category

Consulting$135,475 (99.8%)
Food & Beverage$280.80 (0.2%)
Travel$19.14 (0.0%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $135,475 64 99.8%
Food and Beverage $280.80 17 0.2%
Travel and Lodging $19.14 1 0.0%

Top Paying Companies

Company Total Records Latest Year
Takeda Pharmaceuticals U.S.A., Inc. $122,280 56 $0 (2024)
Shire North American Group Inc $13,214 9 $0 (2019)
Greenwich Biosciences, Inc. $211.02 13 $0 (2021)
Kyowa Kirin, Inc. $49.27 3 $0 (2021)
CSL Behring $20.51 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $27,360 12 Takeda Pharmaceuticals U.S.A., Inc. ($27,360)
2023 $18,040 8 Takeda Pharmaceuticals U.S.A., Inc. ($18,040)
2022 $26,160 12 Takeda Pharmaceuticals U.S.A., Inc. ($26,160)
2021 $25,855 18 Takeda Pharmaceuticals U.S.A., Inc. ($25,760)
2020 $25,086 20 Takeda Pharmaceuticals U.S.A., Inc. ($24,960)
2019 $13,275 12 Shire North American Group Inc ($13,214)

All Payment Transactions

82 individual payment records from CMS Open Payments — Page 1 of 4

Date Company Product Nature Form Amount Type
12/09/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
11/13/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
10/09/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
09/11/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
08/09/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
07/12/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
06/10/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
05/10/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
04/17/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
03/11/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
02/14/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
01/17/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
12/15/2023 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
11/10/2023 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
10/09/2023 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
09/13/2023 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
07/14/2023 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
06/14/2023 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,280.00 General
04/07/2023 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,180.00 General
02/08/2023 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,180.00 General
12/07/2022 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,180.00 General
11/09/2022 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,180.00 General
10/05/2022 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,180.00 General
09/09/2022 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,180.00 General
08/17/2022 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $2,180.00 General

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2020 2 23 23 $866.60 $171.91
Total Patients
23
Total Services
23
Medicare Billing
$171.91
Procedure Codes
2

All Medicare Procedures & Services

2 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
73502 X-ray of hip with pelvis, 2-3 views Facility 2020 11 11 $440.00 $94.95 21.6%
73560 X-ray of knee, 1 or 2 views Facility 2020 12 12 $426.60 $76.96 18.0%

About Dr. Matthew Cherry, D.O

Dr. Matthew Cherry, D.O is a Diagnostic Radiology healthcare provider based in Springfield, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457376865.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Cherry, D.O has received a total of $135,775 in payments from pharmaceutical and medical device companies, with $27,360 received in 2024. These payments were reported across 82 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($135,475).

As a Medicare-enrolled provider, Cherry has provided services to 23 Medicare beneficiaries, totaling 23 services with total Medicare billing of $171.91. Data is available for 1 year (2020–2020), covering 2 distinct procedure/service records.

Practice Information

  • Specialty Diagnostic Radiology
  • Location Springfield, MO
  • Active Since 07/13/2006
  • Last Updated 09/26/2016
  • Taxonomy Code 2085R0202X
  • Entity Type Individual
  • NPI Number 1457376865

Products in Payments

  • Epidiolex (Drug) $211.02
  • NOURIANZ (Drug) $49.27
  • Hizentra (Biological) $20.51

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Diagnostic Radiology Doctors in Springfield